SI-BONE, Inc.
Financials
Valuation Metrics
SI-BONE, Inc.'s Market Cap is $802M. At end of 2025 it was $858M. Ranked #2592 of 3,121 in US market (top 83%), #1092 of 1,463 on NASDAQ (top 75%), #160 of 205 in Health Care Equipment & Services (top 78%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $802M | US#2,592/3,121 Sec#160/205 |
| Revenue | $214M | US#2,565/3,121 Sec#168/205 |
| Net Income | $-15M | US—/3,121 Sec—/205 |
| Total Assets | $249M | US#2,960/3,121 Sec#182/205 |
| Net Assets | $182M | US#2,711/3,121 Sec#163/205 |
| Employees | 376 | US#2,356/3,121 Sec#163/205 |
| Value | ||
| P/B | 4.40x | US#2,107/3,121 Sec#122/205 |
| P/S | 3.76x | US#2,009/3,121 Sec#136/205 |
| FCF Yield | -0.55% | US—/3,121 Sec—/205 |
| Profitability | ||
| ROE | -8.03% | US#2,331/3,121 Sec#129/205 |
| ROA | -5.88% | US#2,562/3,121 Sec#143/205 |
| Op. Margin | -8.31% | US#2,531/3,121 Sec#152/205 |
| Revenue Growth | 15.30% | US#903/3,121 Sec#61/205 |
| Financial Health | ||
| Debt Ratio | 36.42% | US#419/3,121 Sec#45/205 |
| Total Debt | $7M | US#2,871/3,121 Sec#190/205 |
| FCF | $-4M | US#2,348/3,121 Sec#148/205 |
| Cash | $33M | US#2,735/3,121 Sec#178/205 |
| Current Ratio | 9.15x | US#287/3,121 Sec#14/205 |
| Performance | ||
| 1Y Return | 19.17% | US#1,095/3,121 Sec#87/205 |
| 1M Return | -9.14% | US#1,852/3,121 Sec#146/205 |
| From 52W High | -17.36% | US#1,324/3,121 Sec#92/205 |
| 1Y MDD | -45.75% | US#2,277/3,121 Sec#136/205 |
| Trading | ||
| Volume | 708,932 shares | US#1,872/3,121 Sec#127/205 |
| Trading Value | $13M | US#2,303/3,121 Sec#156/205 |
| Per Share | ||
| EPS | $-0.33 | US—/3,121 Sec—/205 |
| BPS | $4.11 | US#2,353/3,121 Sec#149/205 |
Company Info
SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.